70 results
6-K
EX-99.3
ADAP
Adaptimmune Therapeutics Plc
9 Oct 15
Adaptimmune announces New Research and Development Facility in Oxfordshire
12:00am
to be working in partnership with key players in Pennsylvania and we regard our commitment to The Navy Yard as a vote of confidence in the city … located at 2001 Market Street, while the development of the new facility at The Navy Yard is completed.
“Adaptimmune has shown a true commitment
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
these matters with the chairman.
TIME COMMITMENT
You will be expected to devote such time as is necessary for the proper performance of your duties … with the chairman.
page 3 of 13
The nature of the role makes it impossible to be specific about the maximum time commitment. You may be required to devote
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Jul 18
Departure of Directors or Certain Officers
5:00pm
discuss these matters with the chairman.
2. TIME COMMITMENT
2.1 You will be expected to devote such time as is necessary for the proper performance … commitment. You may be required to devote additional time to the Company in respect of preparation time for meetings and ad hoc matters that may arise
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
your role, you should discuss these matters with the chairman.
TIME COMMITMENT
You will be expected to devote such time as is necessary for the proper … commitment. You may be required to devote additional time to the Company in respect of preparation time for meetings and ad hoc matters that may arise
8-K
EX-10.3
h1ys3zhex742ni329p6e
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
l9rtmn6
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.3
a4ofx1gwjvjmhy
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
nua 8vo64x
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-10.2
y46vm1ud1ijkis2 ln2
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-99.1
6lr58262 6rgmtzvq8z
5 Nov 20
Adaptimmune Reports Q3 Financial Results and Business Update
7:40am
8-K
EX-99.1
qdpzbzlcso
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
5q4hs37
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
DRS
EX-10.2
4ox56kdybs vrchyxix
5 Feb 15
Draft registration statement
12:00am